PharmGen Science, Inc.

As of June 30, 2026, PharmGen Science, Inc. carries a market capitalization of 63.98B, placing it among publicly traded companies globally. Its enterprise value stands at 44.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PharmGen Science, Inc. has 21.91M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.35, and the price-to-book ratio stands at 0.46.

As of June 30, 2026, PharmGen Science, Inc. trades at an EV/EBITDA multiple of 5.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 44.63B versus a market cap of 63.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PharmGen Science, Inc. maintains a current ratio of 3.33, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, PharmGen Science, Inc. posted a negative return on equity (ROE) of -69.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.17, reflecting losses generated across the asset base. The company generates approximately 745.42M in revenue per employee across its workforce of 235.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.03 indicates how many times PharmGen Science, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PharmGen Science, Inc. recorded an income tax benefit of -35.20B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -169.56B and -134.36B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, PharmGen Science, Inc.'s stock has declined approximately 31.73% over the past 52 weeks. The 50-day moving average sits at 3,009.80, while the 200-day moving average is 3,513.18.

Over the twelve months ended June 30, 2026, PharmGen Science, Inc. generated 175.36B in revenue and converted that into -134.36B in net income, yielding earnings per share of -6,087.64. EBITDA reached 8.88B, while operating income came in at 4.19B.

As of June 30, 2026, PharmGen Science, Inc. holds 20.05B in cash and equivalents against 698.14M in total debt, resulting in a net debt position of -19.52B. Total book value stands at 140.04B, with working capital of 64.37B providing operational flexibility.

PharmGen Science, Inc. produced 17.33B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.08B in capital expenditures, free cash flow totaled 13.24B - equivalent to 630.39 per share.

Over the twelve months ended June 30, 2026, PharmGen Science, Inc. posted a gross margin of 65.15, reflecting its pricing power and cost economics. The operating margin of 2.39 and net profit margin of -76.62 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 20.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.47, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmGen Science, Inc. shareholders.

PharmGen Science, Inc.'s most recent stock split took place on December 9, 2014 with a 10:1 split ratio.

As of June 30, 2026, PharmGen Science, Inc. has an Altman Z-Score of 2.42, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.